Both IgAN and HIV-infected patients had increased IgA-binding to collagen types II, III, and VI. Preabsorption of the sera with gelatin substantially reduced the IgA-binding to collagen types Ito IV, but not to types V and VI. This finding suggests that the binding to collagen type V is not fibronectin-mediated, but may reflect autoantibody formation. Thus, fibronectin-mediated IgA-collagen interactions are not specific for IgAN, and their pathogenetic role is questionable. The role of IgA anti-collagen type V antibodies requires further study.
Primary IgA nephropathy (IgAN) is a common form of glomerulonephritis with a varied spectrum of clinical presentations, leading to a slowly progressive renal failure in a substantial proportion of patients [1] . The disease is characterized by deposits of IgAl, derived from the blood stream, in the glomerular mesangium [2, 3] . Although increased plasma levels of IgAl and IgAl-containing immune complexes are thought to be of pathogenetic importance, the mechanism of the mesangial deposition remains unclear [3] [4] [5] [6] [7] [8] [9] [10] [11] . Certainly, elevated plasma levels of IgAl or IgA 1-containing immune complexes alone are not sufficient to cause mesangial deposition of IgAl, as witnessed by the rare occurrence of IgAN in patients with IgA 1 myeloma or infection with the human immunodeficiency virus type I (HIV) [12, 13] . Despite the numerous renal biopsy or autopsy specimens examined from HIV-infected patients, mesangial deposits of IgA have only rarely been found [14] [15] [16] [17] [18] [19] .
To inactivate HIV in the serum samples, Nonidet NP4O (Sigma Chemical Company, St. Louis, Missouri, USA) was added to a final concentration of 0.1%. To insure comparability between the groups, the sera in the IgAN and control groups were similarly treated. The sera were stored at -20°C until the time of the study. The total serum concentrations of IgG, IgA, and 1gM were measured by rate nephelometry using commercial standards.
Extracellular matrix preparations
Native collagen types I to VI were isolated from human tissues by partial proteolysis and sequential salt precipitation, and characterized by published methods [24] . Collagen types I and III were isolated from amnion. Collagen type IV was isolated from chorion, and types V and VI were isolated from whole placenta. Collagen type II was isolated from a human chondrosarcoma. Stock solutions were maintained in 0.5 M acetic acid at 4°C. A kidney extract was prepared from the renal cortex of the unaffected portion of a nephrectomy specimen from an 8-month-old White female with a Wilms' tumor. The tissue was stored at -70°C until use. Approximately 400 mg of tissue was minced with a scalpel blade and washed twice in cold phosphate buffered saline (PBS) to remove serum proteins. The tissue fragments were resuspended in 1 ml Tris-HC1 buffer (pH 8.0) containing 1% sodium dodecyl sulfate and 5% f3-mercaptoethanol. After homogenization in a glass tissue grinder, the mixture was boiled for five minutes and cooled on ice. Remaining particulate matter was removed by centrifugation, and the supernatant aliquoted and stored at -20°C. The total protein content was measured according to Lowry's method. The extract contained negligible quantities of immunoglobulins, as determined by enzyme-linked immunosorbent assay (ELISA).
Enzyme-linked immunosorbent assay
Polystyrene microtiter plates (Linbro/Titertek, Flow Laboratories, McLean, Virginia, USA) were coated overnight at room temperature with 100 p1/well of the individual matrix preparations at a concentration of 10 gIml in borate buffered saline (pH 8.5) [25] . After washing with PBS (pH 7.2), the wells were blocked for four hours at 37°C and overnight at 4°C with 200 p1/well of PBS containing 0.15% Tween 20 (Sigma) and 1% bovine serum albumin (BSA) (Sigma) (PBS-Tween-BSA). This buffer was also used as a diluent in all subsequent steps of the ELISA. Between each of the following steps in the ELISA, the plates were washed six times with PBS containing 0.15% Tween 20 in an automated plate washer (Dynatech Laboratories, Inc., Chantilly, Virginia, USA). The sera were diluted 1:100 (or higher if high levels of immunoglobulin binding were detected), and assayed in duplicate wells at 100 p1/well. After an overnight incubation at 4°C, bound immunoglobulins were detected with affinity-purified, biotin-labelled goat F(ab)2 fragments specific for the heavy chains of human IgG, IgA, or 1gM (Tago Inc., Burlingame, California, USA). The incubation with the biotinylated antibodies was performed at 37°C for two hours, and followed by avidin-conjugated peroxidase (Sigma) for one hour at 37°C. Conversion of the substrate [2,2'-azino-bis (3-ethylbenzthiazoline-6-sulfonic acid) (Sigma), containing 0.0075% H202)] was measured at 414 nm on an Anthos 2001 plate reader (Anthos Labtec Instruments, Salzburg, Austria). For each type of ELISA, characterized by matrix preparation and isotype, a serum with a high degree of binding was selected as a standard and assigned a titer of 3200 arbitrary U/ml. This standard serum was included in duplicate on each plate in seven twofold dilution steps, to construct a standard curve. OD readings of blanks, obtained in wells containing no serum, were subtracted from the OD values in the wells containing standards and unknowns. The titers in the test sera were obtained by interpolation on the standard curves using a four-parameter modelling procedure (Deltasoft, BioMetallics Inc., Princeton, New Jersey, USA). Sera with titers less than 25 U/ml (the lower detection limit) were arbitrarily assigned a titer of 25 U/ml for the statistical analysis. In preliminary experiments, all sera were also measured in wells which had been treated only with the blocking solution, and the binding of IgG, IgA, and 1gM was negligible.
Inhibition ELISA
The specificity of the ELISA used in this study was further tested by inhibiting the binding of IgA to the solid phase after a preincubation of sera, selected for a high level of IgA binding, with the homologous type of collagen. The sera were diluted 1:100 in PBS-Tween-BSA containing increasing concentrations of the inhibitor collagen. After incubation overnight at 4°C, the samples were assayed in the ELISA described above. In addition, heterologous inhibition was examined: the binding to collagen types II to VI was inhibited by increasing concentrations of collagen type I. Similarly, the binding to collagen type I was inhibited by increasing concentrations of collagen type V. In all inhibition studies, the remaining IgA binding to the solid phase after inhibition was expressed as a percentage of the OD value in the original serum.
Absorption to gelatin and anti-fl bronectin
To investigate the mechanism of the binding of IgA to the collagens and the possible role of fibronectin-IgA aggregates, we performed affinity-absorption experiments on 16 sera (8 IgAN and 8 HIV) selected for the highest level of IgA-binding to collagen type V. The sera were first absorbed to gelatin (Sigma) coupled to Sepharose CL-4B beads (Pharmacia Fine Chemicals, Piscataway, New Jersey, USA) (approximately 5 mg gelatin/ml gel) to allow fibronectin-IgA aggregates to bind to the fibronectin-binding sites on denatured collagen type I [21, 26, 27] . As a control, the sera were absorbed in parallel to BSA coupled to Sepharose CL-4B beads. All absorptions were performed in microcentrifuge tubes by overnight rotation at 4°C, followed by centrifugation and harvesting of the supernatants. A ratio of packed immunoabsorbent to serum of approximately 1:4 was used, as this has previously been shown to remove more than 80% of the total fibronectin from serum samples (L.M. Switalski and M. Hook, unpublished observations). After the first absorption to gelatin, a second absorption to monospecific, polyvalent rabbit anti-fibronectin IgG coupled to Sepharose CL-4B beads (approximately 2 mg IgG/ml gel) was performed in a similar fashion, to achieve more complete removal of all fibronectin-containing material from the sera. The second absorption was performed on an aliquot of the supernatant after the gelatin absorption, with a second aliquot being absorbed to the control immunoabsorbent BSA. In this fashion, a total of five samples, including the pre-absorption the kidney specimen used for the preparation of the kidney extract were fixed in 96% ethanol containing 5% glacial acetic acid for 20 minutes at -20°C. After washing with PBS, the sections were overlayed with a 1:10 dilution of the sera in PBS containing 1% BSA. As a negative control, we used a 1:10 dilution of pooled normal human serum. Following the 30 minute incubation, the sections were washed and stained with a goat F(ab)2 anti-human IgA antibody coupled to fluorescein isothiocyanate (Southern Biotechnology Associates, Inc., Birmingham, Alabama, USA). The intensity of staining for IgA was judged independently by two observers by fluorescence microscopy.
Statistical analysis
The U/mI obtained in the various ELISA's indicated that the probability distributions were not normal, but followed rightskewed distributions whose standard deviations appeared to be roughly linear with the means. Transformation of these data to their common logarithms appeared to yield values whose variances were more homogeneous from group to group and which were more nearly normally distributed. Values that were below the threshold for an assay were set to the lowest detectable reading (25 U/ml) before being transformed. There were four groups for comparison: White patients in each of the IgAN, HIV-infected and control groups, and Black HIV-infected patients. The comparisons chosen were: comparison among the three groups of White individuals, and comparison of Black versus White patients in the HI V-infected group. Racial differences were often found among the HIV-infected patients, making it inappropriate to pooi over race in the disease group comparisons. Consequently, comparisons among the three disease groups were made only in the White individuals. Significance levels for these comparisons were initially determined using contrasts to define each of the individual comparisons. A Bonferroni multiple comparisons adjustment was used for the three paired comparisons among the White individuals. The basic statistical analysis used was an analysis of covariance for a two-way classification with unequal subclass number. Gender and the four groups with their interaction were the fixed effects of interest, and age was used as a covariate. Results were expressed as adjusted geometric means with their asymptotic standard errors. A second analysis was also performed in which the total serum IgA concentration was an additional covariate.
Correlations among the various parameters were assessed using principal component analysis of the correlation matrices for the log-transformed data. These were done with two types of parameter groupings: with the three different isotypes together that were measured on the same ECM preparation, and with the ECM preparations together that were measured for binding of the same isotype, Tests for differences in relationship of a pair of parameters among the groups were done by testing for differences in slope using analysis of covariance methods.
Specificity of the assays
Background binding of immunoglobulins to blocked uncoated wells was negligible for all sera. Although direct comparisons between the amounts of immunoglobulin bound to the various ECM preparations were not possible, the much slower color development noted in the collagen type IV ELISA for all isotypes suggested a considerably lower degree of binding than with the other types of ECM preparation. The binding of IgA to the collagen types Ito VI was inhibited by increasing amounts (0.5 to 50 j.g/ml) of the same ligand in a dose-dependent fashion.
For collagen type I the mean percentage of binding remaining after inhibition with 50 tg/ml of collagen type I was 4% (N = 6). For collagen type V the mean remaining percentage was 25% (N = 6). For each of the remaining types of collagen three sera were studied. The mean remaining binding levels at 50 g/ml of the inhibitor were: collagen type II 22%; collagen type III 16%; collagen type IV 47%; collagen type VI 30%. These findings demonstrate that the binding to the collagens on the solid phase was specific, although it does not explain the mechanism of the collagen-immunoglobulin interaction.
In addition, we studied heterologous inhibition. Collagen type I at 50 g/ml substantially inhibited the binding to collagen types II to IV: for collagen type lithe mean remaining percentage was 27%; for collagen type III 13%; for collagen type IV 21%. In contrast, the inhibition of the IgA binding to collagen types V and VI by collagen type I at 50 Wml was much less effective: for collagen type V the mean remaining percentage was 64%; for collagen type VI 88%. However, when collagen type V was used as an inhibitor at 50 g/ml in the collagen type I binding assay, the inhibition was nearly complete, with a mean remaining percentage of 3%. The inhibition studies for the collagen types I and V are presented in Figure 1 .
Comparison of the patient groups The main differences in the level of immunoglobulin binding to the various preparations of ECM components were in the IgA isotype. IgAN patients had significantly higher binding of IgA to the collagen types I and V than both healthy controls and the HIV-inlected patients. The binding to the kidney extract was highest in the IgAN group, intermediate in the HIVinfected patients, and lowest in the healthy controls, with statistically significant differences between all three groups.
The binding of IgA to collagen types II, III, and VI was significantly elevated in both the IgAN and the HIV patients when compared with the healthy controls. The level of IgA binding to collagen types II, III, and VI did not significantly differ between the IgAN and HIV groups. The results for the 3 isotypes are summarized in Table 1 .
The levels of binding to the ECM preparations for IgG and 1gM showed few statistically significant differences between the patient groups. The IgAN and the HIV patients had diminished binding of IgG to collagen type VI, and of 1gM to collagen type IV when compared with the healthy controls. The HI V-positive patients showed decreased binding of IgG to collagen type II compared with the IgAN patients and healthy controls. Inhibitor, g/m/ 
Total serum immuno globulin concentrations
As shown in Table 2 , the IgAN patients had significantly higher levels of IgA than the healthy control group, while the HIV-infected patients had significantly elevated levels of IgG, IgA, and 1gM when compared with both the healthy controls and the IgAN patients.
Correlations between the various parameters 0 0. 5 5 50 to all of the ECM preparations when the data from the three groups were taken together. Within each of the three groups these significant positive correlations remained, with two exceptions: in the healthy control group the binding to collagen type I was only weakly correlated to total IgA (r = 0.31; P = 0.13), and in the HIV-infected patients the correlation between binding to collagen type V and total IgA was even weaker (r = 0.11; P = 0.59). In order to mathematically adjust for this effect A statistically significant positive correlation was found be-of total IgA concentration on the levels of IgA binding, we tween the total IgA concentration and the level of IgA binding repeated the statistical analysis with the total IgA concentration (17) 49 (7) 55 (11) included as a covariate in the model. As shown in Table 3 , the increased IgA binding to collagen types I to III found in the unadjusted data was no longer apparent when this correction for total IgA concentration was made. Nevertheless, the increased binding of IgA to collagen types V and VI and to the kidney extract remained, and became exclusive for the IgAN patients.
When the data from all three groups were taken together, the total 1gM concentrations also showed significant positive correlations to the binding of 1gM to all of the ECM preparations. The same analysis for IgG revealed weak positive correlations that were statistically significant only for the collagen types III to V and for the kidney extract.
The binding of IgA to one ECM preparation in general also showed a significant positive correlation to the level of binding to the other ECM preparations. In the healthy controls and the IgAN patients, the level of IgA binding to a given ECM preparation was generally positively correlated to the level of IgG binding to the same preparation. In contrast, the level of 1gM binding generally showed negative or absent correlations with the levels of IgA and IgG binding to the same ECM preparation. In the HIV-infected patients, all three isotypes generally showed positive correlations in their binding to the same ECM preparation.
Role offibronectin in the collagen-IgA interaction The results of the affinity-absorption of eight IgAN and eight HIV-positive sera, selected for high degrees of IgA binding to collagen type V, are shown in Figure 2 . Absorption to gelatin substantially reduced the amount of IgA binding to the collagen types Ito IV in both patient groups. By contrast, the amount of IgA binding to the collagen types V and VI was not significantly influenced by gelatin absorption. The subsequent incubation of the gelatin-absorbed sera with anti-fibronectin coated beads did not further reduce the IgA-binding to any of the collagen types, suggesting that the removal of IgA-fibronectin aggregates was complete after the first absorption. For each of the 16 sera the U/ml after the gelatin absorption was expressed as a percentage of the U/ml remaining after the control absorption to BSA. This percentage measures the effect of the removal of fibronectin from the serum on the binding to collagens. The results for IgAN and HIV patients are shown in Table 4 .
Effects of age, gender and race
The statistical analysis revealed independent effects of age, gender and race on several of the parameters measured. The level of 1gM binding to all of the ECM preparations showed a significant negative correlation with age. Similarly, the total 1gM concentration was negatively correlated with the age of the individuals. The level of IgA binding to collagen type IV was positively correlated with age. No age effect was found for the binding of IgA to the other ECM preparations, the binding of IgG to ECM preparations, or the total concentrations of IgA and IgG.
Gender proved to have an independent effect on several of the parameters measured. Females had significantly higher concentrations of total 1gM, as well as binding of 1gM to collagen types I, II, III, V, VI, and kidney extract. Likewise, the level of IgG binding to kidney extract was higher in females. However, the binding of IgG to collagen type II was higher in males.
Within the HIV group we studied the effects of race. Such comparisons were not possible in the IgAN and control groups that were comprised of only White individuals. Among the HIV-infected individuals, significantly higher levels were found in Blacks for the following parameters: total IgG concentration, and binding of IgG to collagen types IV, V, and VI. Similarly, Blacks had significantly higher binding of IgA to collagen types IV and V.
Immunofluorescence Glomerular binding of IgA was found in two of the eight IgAN sera. The staining was graded as + to + + (on a scale of 0 to + + +), and was seen in a mixed mesangial and capillary pattern. In addition, one of the two positive sera also showed nuclear staining throughout the kidney specimen. Of the five HIV-positive sera, two showed weak glomerular staining for IgA, and one strong (+ + to + + +) diffuse staining of the entire tissue. Staining was absent in all remaining sera, and in the negative control.
Discussion
The mechanism responsible for the mesangial deposition of IgA in primary IgAN has remained unclear, despite numerous investigations. Although increased levels of total IgAl and IgAl-containing immune complexes in the circulation are thought to be important in this respect, neither factor adequately explains the mesangial deposition [3-111. This shortcoming is clearly illustrated by the general lack of mesangial IgA deposits in diseases characterized by elevated total serum IgAl levels (such as IgAl myeloma), or the combined presence of increased total IgAl and IgA 1-containing immune complexes (such as HIV infection) [12] [13] [14] [15] [16] [17] [18] [19] . The retention of IgAl in the mesangium in IgAN is evidently determined by other characteristics. Possible factors include the antigenic specificity of the IgAl as well as factors unrelated to the specificity. With regard to the antigenic specificity, either exogenous antigens, such as alimentary or microbial components, or endogenous antigens (native to the mesangiuni or non-mesangial) may be implicated. Factors unrelated to the antigenic specificity of the IgAl may include physicochemical properties of the circulating IgA 1, such as size, charge, and glycosylation, or alternatively, biochemical properties of molecules attached to the circulating IgAl, such as fibronectin [211. In general, the search for exogenous antigens in the mesangial deposits has been unrewarding [reviewed in 28]. In the present study, we have sought to identify characteristics of the circulating IgA enabling it to bind to components of the mesangial matrix, by comparing the IgA in sera from IgAN patients to that from sera of healthy controls, and from sera of HI V-infected patients.
Our studies clearly show increased binding of IgA in IgAN sera to a crude extract of normal kidney, and to several purified ECM components (collagen types I, II, III, V, and VI). However, it is of great importance in the interpretation of these data to note that such increased binding of IgA to both the kidney extract and certain collagen types (II, III, and VI) was also found in the sera from HI V-infected individuals. In view of the reported low prevalence of mesangial IgA deposits in HIV infection, this observation implies that the increased binding of IgA to these types of collagen is not relevant to the mesangial deposition. The distinction between the IgAN patients and the HIV patients then centers on the increased binding of IgA to collagen types I and V, found only in the IgAN sera. This greater binding of IgA is startling because the total serum IgA concentration was much higher in the HIV group. This finding suggests that the increased binding to these two types of collagen does not merely reflect a polyclonal stimulation resulting in increased total serum IgA concentrations.
The selectively increased binding of IgA in IgAN sera to collagen type V, an important constituent of human mesangial matrix [29, 30] , may be pathogenetically relevant. The binding of IgA to the crude kidney extract showed significant differences between the three patient groups, with the highest level in the IgAN patients. Because IgAN patients manifested significantly higher binding to this preparation than the HIV patients, the kidney extract may also contain one or more components that are relevant to the mesangial deposition. Future studies using immunoblotting or immunoprecipitation with IgAN sera may identify the responsible components in the extract. The pathogenetic relevance of the increased binding of IgA to collagen type I, which is not present in normal mesangial matrix and appears only in fibrosing lesions [29, 30] , is not apparent.
The binding of IgA to collagen type IV was not significantly increased (P = 0.15) in the IgAN group compared with the other groups. In an earlier study, increased binding to type IV collagen was observed [201. A possible explanation for these discrepant results is that we have used native human collagen type IV, whereas the earlier study used denatured bovine collagen type IV. Although collagen type IV is also a normal constituent of human mesangial matrix [29, 301 , the mesangial deposits of IgA in IgAN biopsies occur at sites distinct from collagen type IV-containing areas [31] . Furthermore, IgA deposition along the glomerular capillary walls, which contain substantial amounts of collagen type IV [29] , is not common in IgAN. Taken together, these findings suggest that collagen type IV is not a target for the binding of IgA in the mesangial matrix.
The molecular mechanism of the increased binding of IgA to the various ECM preparations is uncertain. Theoretically, both an autoantibody type of interaction as well as interactions unrelated to the antigenic specificity might be involved. An important example of the latter is the interaction between collagens and fibronectin complexed to the circulating IgA, first reported by Cederhoim, Bygren and Heinegard [21] . In absorption experiments we attempted to differentiate between these possible mechanisms, and to elucidate the role of IgA-fibronectin aggregates. The finding that preabsorption to gelatin-coated beads markedly reduced the binding to collagen types Ito IV is compatible with fibronectin-mediated binding: gelatin (denatured collagen type I) contains the fibronectin-binding domain of collagen type I and thus may remove IgA-fibronectin aggregates from the sample. The denaturation of collagen type I in the conversion to gelatin destroys the triple helical structure characteristic of collagens, and consequently removes the epitopes against which autoantibodies to native collagen types are directed. Consequently, absorption to gelatin should not affect the titer of true autoantibodies directed at determinants in the native collagen molecule. In the present study, little effect of gelatin absorption was found on the binding of IgA to collagen types V and VI. Similarly, the fluid-phase inhibition experiments showed that collagen type I markedly inhibited the binding of IgA to collagen types I to IV, but had much less effect on types V and VI. These findings suggest that the interaction of serum IgA with the latter types of collagen is not mediated through fibronectin, but rather represents true autoantibodies. To our knowledge, no study has analyzed the relative binding capacities for fibronectin in the various collagen types.
The similarity between the IgAN and HIV groups in their increased binding of IgA to the collagen types II and III raises the question of whether fibronectin-mediated binding plays any role in the binding of IgA to the mesangium in IgAN [211. Based on our data, mesangial deposition of IgA should also occur in HIV-infected patients, if this mechanism is pathogenetically relevant. Alternatively, if binding of IgA to collagen type V is indeed responsible for the mesangial targeting in IgAN, IgA deposits should also be found at other sites in the body with a substantial content of this type of collagen. In this regard, the somewhat controversial finding of vascular IgA deposits in skin and skeletal muscle in IgAN is of interest [32] [33] [34] . Collagen type V is an important constituent of the pericellular matrix of vascular smooth muscle cells [29] . Despite the results in bur study pointing to a possible role for IgA anti-collagen type V autoantibodies, doubt remains concerning their pathogenetic role. First, we were unable to demonstrate consistent binding to the mesangium using immunofluorescence with the selected sera. Secondly, although the profound differences found between the races make comparisons questionable, a very high level of IgA binding to collagen type V and to the kidney extract was also found in the Black HIV patients (Table 1 ). If such binding is pathogenetically relevant, one would have to make the improbable assumption that these Black HIV patients had clinically unnoticed mesangial deposits of IgA.
For the IgG and 1gM isotypes few differences were observed in the levels of binding to the various ECM preparations between the three study groups. The degree of statistical significance was considerably lower than for the differences in the IgA isotype, precluding any firm conclusions. Remarkably, in each of the three instances where significant differences were found, one of the patient groups displayed lower values of binding to the ECM preparation than the healthy control group. Thus, the relevance of this decreased binding, if any, is speculative. One possible explanation is that increased levels of ECM-binding IgA in the patient sera competitively inhibited the binding of other isotypes to the same ligand.
The results of our study with respect to the HIV patients may be at variance with a recent report [35] . In that study, increased binding of IgG to gelatin was reported in HIV-positive individuals and HIV-negative homosexuals. However, an important distinction between the two studies is that we used native collagen preparations, whereas gelatin (denatured collagen type I) was used in the other study. It remains uncertain whether autoantibodies to collagen were measured in that study; perhaps more likely it was a fibronectin-mediated interaction between IgG and gelatin. In support of the latter explanation, fibronectin was a potent inhibitor of the binding of IgG to the gelatin [35] .
The effects of age, gender, and race observed in our results were unexpected, and have not yet been investigated further. A study of these effects clearly should entail a more balanced group composition with regard to gender and race. However, the finding of the effects of age, gender, and race underlines the need to take these factors into consideration in comparable studies in the future.
In summary, we report increased binding of serum IgA to various components of the ECM in patients with IgAN. The mechanism of this increased binding appears in part to be mediated through fibronectin, especially for the non-mesangial collagen types I to III. However, similarly increased IgA binding to these collagen types was also found in sera from patients with HIV infection, a condition not associated with mesangial deposition of IgA. More characteristic for IgAN was increased IgA-biñding to collagen type V (common in mesangial matrix), which was not found in White patients with HIV infection. The interaction between IgA and collagen type V in IgAN may be independent of fibronectin, and perhaps the result of autoantibody formation. However, the pathogenetic role of IgA-collagen interactions in IgAN remains to be elucidated.
